CD300 molecule like family member gGenealiases: CLM-9 · CLM9 · NEPMUCIN · TREM-4 · TREM4
Q-omics provides the consensus-scored CD300LG profile across patient tissues and cancer cell-line models. CD300LG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CD300LG is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CD300LG RNA expression shows 13,291 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where CD300LG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD300LG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD300LG survival associations across molecular data types. CD300LG RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD300LG RNA expression–survival associations across cancer types. High CD300LG expression shows unfavorable associations in OV, but favorable associations in KIRC, KICH, LIHC, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CD300LG RNA expression.
This table summarizes CD300LG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CD300LG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD300LG shows lower tumor expression in HNSC, KICH, BLCA, THCA, KIRC and LUAD. The HNSC box plot shows higher CD300LG RNA expression in normal versus tumor tissue (log2 FC = −0.614, t-test p < 0.001).
This table shows molecular features associated with CD300LG in patient tissues and cancer cell lines. In patient samples, CD300LG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CD300LG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
